Biosimilars: Launch Insights From the Field
How are biosimilar manufacturers approaching patients, providers and payers? What can they do to differentiate? Xcenda shares insight from our field programs.
Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?
Review of HTA Frameworks and Decisions for Next-Generation Sequencing in Precision Oncology
How Digital Innovation Drives Improved Market Access Strategies
In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?
Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions
Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model
The Evolving Healthcare Landscape and the Impact on Patient Access and Affordability
Managing the Growing Expansion of Copay Accumulators
Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments
Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
Therapeutic Spotlight: Assessments of Emerging Therapies for Tardive Dyskinesia
Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division
Emerging Trends in PBM Restrictions on Commercial Copay Assistance
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
Rethink: Payer Strategies for Commercializing Cell and Gene Therapies
Insights from managed care executives on the future of coverage and outcomes evaluation.